Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02997761
Title Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of California, Davis
Indications

B-cell lymphoma

acute lymphoblastic leukemia

Therapies

Blinatumomab + Ibrutinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.